Reprogramming neuroblastoma by diet-enhanced polyamine depletion
Year: 2025
Type: article
Abstract: Neuroblastoma is a highly lethal childhood tumour derived from differentiation-arrested neural crest cells 1,2 . Like all cancers, its growth is fuelled by metabolites obtained from either circulation or local biosynthesis 3,4 . Neuroblastomas depend on local polyamine biosynthesis, and the inhibitor difluoromethylornithine has shown clinical activity 5 . Here we show that such inhibition can be augmented by dietary restriction of upstream amino acid substrates, leading to disruption of oncogenic protein translation, tumour differentiation and profound survival gains in the Th-MYCN mouse model. Specifically, an arginine- and proline-free diet decreases the amount of the polyamine precursor ornithine and enhances tumour polyamine depletion by difluoromethylornithine. This polyamine depletion causes ribosome stalling, unexpectedly specifically at codons with adenosine in the third position. Such codons are selectively enriched in cell cycle genes and low in neuronal differentiation genes. Thus, impaired translation of these codons, induced by combined dietary and pharmacological intervention, favours a pro-differentiation proteome. These results suggest that the genes of specific cellular programmes have evolved hallmark codon usage preferences that enable coherent translational rewiring in response to metabolic stresses, and that this process can be targeted to activate differentiation of paediatric cancers.
Source: Nature
Authors: Sarah Cherkaoui, Christina S. Turn, Yuan Yuan, Wenyun Lu, Lifeng Yang, Matthew J. McBride, Caroline Eigenmann, George E. Allen, Olesya O. Panasenko, Lu Zhang, Annette Vu, Kangning Liu, Yimei Li, Om H. Gandhi, Lea F. Surrey, Sandra D. Kienast, Sebastian A. Leidel, Michael Wierer, Eileen White, Joshua D. Rabinowitz, Michael D. Hogarty, Raphael J. Morscher
Institutions: University of Zurich, University Children's Hospital Zurich, Children's Hospital of Philadelphia, University of Pennsylvania, ETH Zurich, Ludwig Cancer Research, Princeton University, Ludwig Cancer Research, University of Geneva, Institute of Genetics and Genomics in Geneva, Rutgers, The State University of New Jersey, Rutgers Cancer Institute, University of Bern, University of Copenhagen, Innsbruck Medical University, Universität Innsbruck
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $12,690
Funders: U.S. Department of Defense, Deutsches Krebsforschungszentrum, Universität Heidelberg, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Novo Nordisk, EMDO Stiftung, NOMIS Stiftung, Novo Nordisk Fonden, National Institutes of Health, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases
OpenAlex ID: W4414461053
